Reeling from a hefty civil and criminal settlement, Avanir stumbles into PhIII Alzheimer's failure

Avanir’s no good, awful, simply terrible week came to a disastrous end last Friday as the Otsuka subsidiary was forced to report that its second Phase III trial for a new-and-improved version of its commercial drug had failed in treating Alzheimer’s dementia — likely scuttling any future it may have had in the most difficult of all diseases.